|
May 9
|
ICON Public Limited Company (ICLR): Among Steven Cohen’s Mid-Cap Stock Picks with Huge Upside Potential
|
|
May 7
|
ICON Public Limited Company (ICLR): A Bull Case Theory
|
|
May 7
|
Global ICON survey shows need for more efficient obesity clinical trial design to realise full potential of next-gen multi-indication therapies
|
|
Mar 12
|
What makes ICON Public Limited Company (ICLR) an Attractive Investment?
|
|
Mar 10
|
Do Options Traders Know Something About ICON (ICLR) Stock We Don't?
|
|
Feb 21
|
Icon PLC (ICLR) Q4 2024 Earnings Call Highlights: Navigating Challenges with Strategic Growth
|
|
Feb 20
|
ICLR Q4 Earnings and Revenues Beat, Stock Rises at After-Market
|
|
Feb 19
|
Icon PLC (ICLR) Q4 Earnings and Revenues Top Estimates
|
|
Feb 19
|
ICON Reports Fourth Quarter and Full Year 2024 Results
|
|
Feb 18
|
ICON Public Limited Company's (NASDAQ:ICLR) Intrinsic Value Is Potentially 85% Above Its Share Price
|
|
Jan 8
|
What Makes ICON Public Limited Company (ICLR) a Prospective Investment?
|
|
Jan 8
|
Biomarker and Trial Optimisation Needed to Drive R&D Progress in Alzheimer’s and Related Disorders – ICON Survey
|
|
Jan 7
|
Icon price target lowered to $290 from $300 at Citi
|
|
Jan 7
|
ICON plc to Present at the 43rd Annual J.P. Morgan Healthcare Conference
|
|
Dec 31
|
ICON Public Limited Company (ICLR) Slid on Drop in Biotechnology Funding
|